F. Hoffmann-La Roche AG at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

F. Hoffmann-La Roche AG at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
F. Hoffmann-La Roche AG Basel, Switzerland	1 Senior Scientist (pRED)
roche.com\|LinkedIn Public company~112,774 people Roche sells medicines, diagnostic tests, sequencing tools and digital solutions to clinicians, laboratories and healthcare systems. Got FDA clearance for a blood test detecting pTau217, a simpler alternative to PET scans for Alzheimer's diagnosis. › Got FDA clearance for a blood test detecting pTau217, a simpler alternative to PET scans for Alzheimer's diagnosis. 2026-08 · source Launched AXELIOS 1, a new next-generation sequencing platform built on its SBX technology, entering the competitive NGS instrument market. 2026-07 · source Signed an exclusive licensing deal with Nurix Therapeutics for a BTK-degrader drug candidate, adding to its oncology pipeline. 2026-06 · source Source: company newsroom H1 2026 sales CHF 30.4B, up 6% CER › Reported sales fell 2% in Swiss francs on currency; guidance is mid-single-digit growth for 2026. · 2026-07-23 “In the first six months of 2026, Roche sales were +6% at CER, -2% when reported in CHF, to CHF 30.4 billion. / Roche expects an increase in Group sales in the mid single digit range (CER) for 2026.” Source: results release Currently hiring: 1,204 open roles › Source: careers page	Poster Fri Oct 23 2:30 pm Part of Complex Traits and Polygenic Disorders Poster Friday Session Proteomic signature of kidney disease progression in 3,000 diabetic patients from the McGill-BioPortal cohort Exhibit & Poster Hall · Board 8307F Collaborators: Massachusetts General Hospital Complex diseasesDiabetesProteomicsMendelian randomization

Organization

ASHG 2026 Attendance

F. Hoffmann-La Roche AG

Basel, Switzerland

1 Senior Scientist (pRED)

roche.com|LinkedIn

Public company~112,774 people

Roche sells medicines, diagnostic tests, sequencing tools and digital solutions to clinicians, laboratories and healthcare systems.

Got FDA clearance for a blood test detecting pTau217, a simpler alternative to PET scans for Alzheimer's diagnosis.

›

Got FDA clearance for a blood test detecting pTau217, a simpler alternative to PET scans for Alzheimer's diagnosis.

2026-08 · source

Launched AXELIOS 1, a new next-generation sequencing platform built on its SBX technology, entering the competitive NGS instrument market.

2026-07 · source

Signed an exclusive licensing deal with Nurix Therapeutics for a BTK-degrader drug candidate, adding to its oncology pipeline.

2026-06 · source

Source: company newsroom

H1 2026 sales CHF 30.4B, up 6% CER

›

Reported sales fell 2% in Swiss francs on currency; guidance is mid-single-digit growth for 2026. · 2026-07-23

“In the first six months of 2026, Roche sales were +6% at CER, -2% when reported in CHF, to CHF 30.4 billion. / Roche expects an increase in Group sales in the mid single digit range (CER) for 2026.”

Source: results release

Currently hiring: 1,204 open roles

›

Source: careers page

Poster

Fri Oct 23
2:30 pm

Part of Complex Traits and Polygenic Disorders Poster Friday Session

Proteomic signature of kidney disease progression in 3,000 diabetic patients from the McGill-BioPortal cohort

Exhibit & Poster Hall · Board 8307F

Collaborators: Massachusetts General Hospital

Complex diseasesDiabetesProteomicsMendelian randomization